A 1,2,3-Triazole Derivative of Quinazoline Exhibits Antitumor Activity by Tethering RNF168 to SQSTM1/P62

J Med Chem. 2022 Nov 24;65(22):15028-15047. doi: 10.1021/acs.jmedchem.2c00432. Epub 2022 Nov 4.

Abstract

Quinazoline and its derivatives have drawn much attention in the development of potential antitumor agents. Here, we synthesized a series of 1,2,3-triazole derivatives of quinazoline at the C6 position and evaluated for their cytotoxic activity in various human cancer cell lines. We found that compound 5a was the most cytotoxic to HCT-116 cells (IC50, 0.36 μM). Target profiling found that 5a directly binds to both the autophagy-associated protein SQSTM1/P62 and the E3 ligase RNF168, promoting their interaction. Consistently, 5a treatment induces a decrease in RNF168-mediated H2A ubiquitination and compromises homologous recombination-mediated DNA repair, thus increasing the sensitivity of HCT-116 to X-ray radiation. Moreover, 5a suppressed xenografted tumor growth in mice in a dose-dependent manner. Taken together, the 1,2,3-triazole derivative of quinazoline 5a may serve as a novel compound for tumor therapy based on its role in promoting a P62/RNF168 interaction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • DNA Repair*
  • HCT116 Cells
  • Humans
  • Mice
  • Quinazolines* / pharmacology
  • Sequestosome-1 Protein / drug effects
  • Sequestosome-1 Protein / metabolism
  • Triazoles* / pharmacology
  • Ubiquitin-Protein Ligases / drug effects
  • Ubiquitin-Protein Ligases / metabolism
  • Ubiquitination

Substances

  • Quinazolines
  • RNF168 protein, human
  • Sequestosome-1 Protein
  • SQSTM1 protein, human
  • Sqstm1 protein, mouse
  • Triazoles
  • Ubiquitin-Protein Ligases
  • Antineoplastic Agents